Patents Assigned to Merck
  • Buffer solutions for suspensions used in chemical-mechanical polishing
    Patent number: 6338743
    Abstract: The present invention relates to buffer systems in the form of solutions or salts for preparing suspensions which can be used for chemomechanical polishing. In particular, these buffer systems can be used for preparing suspensions having a high pH of 9.5-13 which are used for the chemomechanical polishing of Si and metal surfaces of semiconductors, known as wafers.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: January 15, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Claus Dusemund, Rudolf Rhein, Manuela Schweikert, Martin Hostalek
  • Liquid-crystalline medium
    Publication number: 20020003226
    Abstract: A liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I 1
    Type: Application
    Filed: March 23, 2001
    Publication date: January 10, 2002
    Applicant: Merck Patent GmbH
    Inventors: Michael Heckmeier, Brigitte Schuler, Peer Kirsch, Eike Poetsch
  • Manganese dioxide electrodes, process for producing the same and their use
    Patent number: 6337160
    Abstract: The invention relates to novel manganese dioxide electrodes comprising modified, electrochemically active manganese dioxide, to a method for fabricating these novel manganese dioxide electrodes and to the use of these in rechargeable cells.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: January 8, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter
    Inventors: Volker Hilarius, Gerhard Pfaff, Ralf Glausch, Dietmar Rahner, Waldfried Plieth, Matthias Kloss
  • Triazolo-pyrimidine as ligands for GABA receptors
    Patent number: 6337331
    Abstract: Substituted or 6,7-ring fused 1,2,3-triazolo[1,5-&agr;]-pyrimidine derivatives are selective ligands for GABAA receptors useful in the treatment of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: January 8, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Howard Barff Broughton, Jose Luis Castro Pineiro, Ian James Collins, Karl Richard Gibson, Michael Rowley, Leslie Joseph Street
  • Nucleic acid encoding mouse galanin receptor (GALR2)
    Patent number: 6337206
    Abstract: A new galanin receptor, GALR2, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: January 8, 2002
    Assignees: Merck & Co., Inc., Board of Regents, The University of Texas System
    Inventors: Carina Tan, Lee F. Kolakowski, Jr.
  • Lithium salt and a process of preparing thereof
    Publication number: 20020001755
    Abstract: The invention can relate to lithium salts of the general formula (I)
    Type: Application
    Filed: April 5, 2001
    Publication date: January 3, 2002
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Udo Heider, Michael Schmidt, Andreas Kuhner, Dagmar Petigk
  • Method for large scale plasmid purification
    Publication number: 20020001829
    Abstract: A process is disclosed for the large scale isolation and purification of plasmid DNA from large scale microbial fermentations. All three forms of plasmid DNA; supercoil (form I), nicked or relaxed circle (form II), and linearized (form III), are individually isolatable using the disclosed process. Highly purified DNA suitable for inclusion in a pharmaceutical composition is provided by the disclosed process.
    Type: Application
    Filed: March 6, 2001
    Publication date: January 3, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Ann L. Lee, Sangeetha Sagar
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Publication number: 20020002164
    Abstract: Substituted heterocycles of the general structural formula: 1
    Type: Application
    Filed: April 17, 2001
    Publication date: January 3, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Inhibitors of prenyl-protein transferase
    Patent number: 6335343
    Abstract: The present invention comprises piperazine/piperazinone-containing compounds having multicyclic ring system substituents on one of the piperazine/piperazinone nitrogens, which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: January 1, 2002
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, Jr., Anthony M. Smith, John T. Sisko
  • Pigment mixture
    Patent number: 6334893
    Abstract: The present invention relates to pigment mixtures containing at least two components component A being Al2O3 flakes coated with one or more metals, metal oxides and/or metal sulfides and component B being acicular or spherical colorants, and to their use in particular in varnishes, paints, printing inks, powder coating materials, plastics and cosmetic formulations.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: January 1, 2002
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Gerhard Pfaff, Sabine Schoen, Kaiman Shimizu
  • Cyclic peptide derivatives
    Patent number: 6333308
    Abstract: Compounds of the formula I cyclo-(Arg-X-Asp-R1)  I in which X is Gly, Ala or NH—NH—CO, R1 is a radical of the formula II  and R2,R3 and R4 have the meanings indicated in claim 1, and their salts, can be used as integrin inhibitors, in particular for the prophylaxis and treatment of disorders of the circulation, in thrombosis, cardiac infarct, coronary heart disorders, arteriosclerosis, in pathological processes which are supported or propagated by angiogenesis and in tumour therapy.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: December 25, 2001
    Assignee: Merck KGaA
    Inventors: Gunter Holzemann, Claus Fittschen, Simon Goodman
  • 3-Benzylpiperidine
    Patent number: 6333339
    Abstract: The invention relates to piperidine derivatives of the formula I in which R1, R2, m and k have the meanings indicated in claim 1, and their salts, novel intermediates and processes for the preparation of the compounds according to the invention. The compounds of the formula I are potent a receptor ligands and show 5-HT reuptake-inhibiting actions and can be used for the production of medicaments, for example for the treatment of disorders of the central nervous system, of strokes, brain or bone marrow traumata or of ischaemic states.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: December 25, 2001
    Assignee: Merck Patent Gellschaft mit Beschrankter
    Inventors: Henning Boettcher, Helmut Pruecher, Hartmut Greiner, Christoph Seyfried, Andrew Barber, Joseph Maria Martinez
  • Method for inhibiting bone resorption
    Patent number: 6333316
    Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: December 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
  • Prolines as antimicrobial agents
    Patent number: 6333344
    Abstract: Transfer ribonucleic acid (tRNA) synthetase inhibitors, salts, and pharmaceutically acceptable compositions thereof of the general formula: wherein Ar is aryl and heteroaryl; L is —C(O)N(Q)CH2—, or —CR10R11OCR12R13—; Q is hydrido, —(CH2)mCO2H and —(CH2)mCO2CH3, m is 1, 2, 3, and 4; R1, R2, R9, R10, R11, R12 and R13 are hydrido or lower alkyl; wherein Het is a heterocyclic moiety, the inhibitors are suitable for use as antimicrobial agents.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: December 25, 2001
    Assignees: Merck & Co., Cubist Pharmaceuticals, Inc.
    Inventors: Milton L. Hammond, Aaron H. Leeman, Milana Maletic, Gina M. Santorelli, Sherman T. Waddell, John Finn, Michael Morytko, Siya Ram, Dennis Keith
  • Phenyl-protein transferase inhibitors
    Patent number: 6333335
    Abstract: The present invention is directed to tetrahydro-imidazopyridinyl compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: December 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, Samuel L. Graham, Theresa M. Williams
  • Pyrazolo-pyridine derivatives as ligands for GABA receptors
    Patent number: 6333336
    Abstract: Pyrazolo[4,3-c]pyridin-3-one derivatives substituted at the 2-position by an optionally substituted aryl or heteroaryl moiety, and having pendant substituents at the 7-position and optionally also at the 6-position, are selective ligands for GABAA receptors, particularly having high affinity for the &agr;2 and/or &agr;3 subunit, and are useful in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: December 25, 2001
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Wesley Peter Blackaby, Jose Luis Castro Pineiro, Richard Thomas Lewis, Michael Geoffrey Neil Russell, Leslie Joseph Street
  • Process of synthesizing binaphthyl derivatives
    Patent number: 6333435
    Abstract: A process of synthesizing a compound of the formula 1: is disclosed, which comprises reacting a compound of the formula 2: with diphenylphosphine in the presence of an amine base and a nickel catalyst to produce a compound of formula 1.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: December 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Dongwei Cai, David L. Hughes, Sylvain Levac, Thomas R. Verhoeven
  • Text influenced molecular indexing system and computer-implemented and/or computer-assisted method for same
    Patent number: 6332138
    Abstract: An extension of the vector space model for computing chemical similarity using textual and chemical descriptors is described. The method uses a chemical and/or textual description of a molecule/chemical and a decomposes a molecule/chemical descriptor matrix by a suitable technique such as singular value decomposition to create a low dimensional representation of the original descriptor space. Similarities between a user probe and the textual and/or chemical descriptors are then computed and ranked.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: December 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Richard D. Hull, Eugene M. Fluder, Jr., Suresh B. Singh
  • Method for inhibiting dental resorptive lesions
    Patent number: 6331533
    Abstract: The present invention relates to a method for inhibiting dental resorptive lesions and other disease states associated with dental resorptive lesions in a mammal by administering a therapeutically effective amount of a bisphosphonate or a pharmaceutically acceptable salt thereof to a mammal in need thereof. This invention also relates methods of alleviating of pain and reducing the risk of tooth loss associated with dental resorptive lesions in mammals.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: December 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Colin E. Harvey, Kenneth L. Mohn
  • Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
    Patent number: 6329421
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: December 11, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Petpiboon Prasit, Daniel Guay, Zhaoyin Wang, Serge Leger, Michel Therien